These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11948963)

  • 1. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
    Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
    Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
    Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
    Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
    Miyake Y; Kodama T; Yamaguchi K
    Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
    J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer.
    Naumnik W; Chyczewska E; Izycki T; Ossolinska M
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():88-90. PubMed ID: 15638385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProGRP: a new biomarker for small cell lung cancer.
    Molina R; Filella X; Augé JM
    Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.